Activin and Inhibin

GSK163090 is a potent, selective and orally active 5-HT 1A/1B/1D receptor antagonist with pK i values of 9.4/8.5/9.7, respectively. GSK163090 inhibits the functional activity of serotonin reuptake transporter (SerT) with a pK i value of 6.1.

GSK163090 is a potent, selective and orally active 5-HT 1A/1B/1D receptor antagonist with pK i values of 9.4/8.5/9.7, respectively. GSK163090 inhibits the functional activity of serotonin reuptake transporter (SerT) with a pK i value of 6.1.

GSK163090 is a potent, selective and orally active 5-HT 1A/1B/1D receptor antagonist with pK i values of 9.4/8.5/9.7, respectively. GSK163090 inhibits the functional activity of serotonin reuptake transporter (SerT) with a pK i value of 6.1.

GSK163090 is a potent, selective and orally active 5-HT 1A/1B/1D receptor antagonist with pK i values of 9.4/8.5/9.7, respectively. GSK163090 inhibits the functional activity of serotonin reuptake transporter (SerT) with a pK i value of 6.1.

GSK163090 is a potent, selective and orally active 5-HT 1A/1B/1D receptor antagonist with pK i values of 9.4/8.5/9.7, respectively. GSK163090 inhibits the functional activity of serotonin reuptake transporter (SerT) with a pK i value of 6.1.

GSK1790627 is the N-deacetylated metabolite of Trametinib ( HY-10999 ). Trametinib is an orally active MEK inhibitor, and activates autophagy and induces apoptosis.In VitroGSK1790627 (1, 10 and 50 μM, 60 min) is stable in the presence of recombinant

GSK1790627 is the N-deacetylated metabolite of Trametinib ( HY-10999 ). Trametinib is an orally active MEK inhibitor, and activates autophagy and induces apoptosis.In VitroGSK1790627 (1, 10 and 50 μM, 60 min) is stable in the presence of recombinant

GSK1790627 is the N-deacetylated metabolite of Trametinib ( HY-10999 ). Trametinib is an orally active MEK inhibitor, and activates autophagy and induces apoptosis.In VitroGSK1790627 (1, 10 and 50 μM, 60 min) is stable in the presence of recombinant

GSK1790627 is the N-deacetylated metabolite of Trametinib ( HY-10999 ). Trametinib is an orally active MEK inhibitor, and activates autophagy and induces apoptosis.In VitroGSK1790627 (1, 10 and 50 μM, 60 min) is stable in the presence of recombinant

GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase ( SCD ) inhibitor extracted from patent WO/2009060053 A1, compound example 16.In VitroGSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD), which can be used to treat and/or

GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase ( SCD ) inhibitor extracted from patent WO/2009060053 A1, compound example 16.In VitroGSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD), which can be used to treat and/or

GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase ( SCD ) inhibitor extracted from patent WO/2009060053 A1, compound example 16.In VitroGSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD), which can be used to treat and/or